Trial Profile
A Single-centre, Retrospective, Cohort study to evaluate the conversion from Calcineurin Inhibitor to Belatacept in kidney transplant recipients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2018
Price :
$35
*
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 12 Jul 2018 New trial record
- 06 Jun 2018 Results assessing 12-month evolution of Anti-HLA Antibodies Donor Specific Antibodies after rescue conversion from Calcineurin Inhibitor to Belatacept (n=47) presented at the 2018 American Transplant Congress
- 06 Jun 2018 Results assessing the effect and reasons of rescue switch from Calcineurin Inhibitor to Belatacept (n=73) presented at the 2018 American Transplant Congress